NEOADJUVANT FOR PATIENTS WITH HIGH AND VERY HIGH RISK PROSTATE CANCER. Вопр. онкол. 2019, 65 (5), 726-735. https://doi.org/10.37469/0507-3758-2019-65-5-726-735.